EarningsBarfresh Food Group Inc. reports disappointing 4Q23 results, leading to reduced estimates and a lower price target, despite maintaining a buy rating based on the potential of expanded products and opportunities in the education channel.
Financial PerformanceCryo-Cell International, Inc. faces a setback as F4Q EBITDA misses expectations, largely due to one-time non-cash charges and delayed clinic revenue, resulting in a lowered price target while still recognizing the potential in stem cell opportunities.
Stock ValuationLongeveron Inc. sees a price target cut to $1.50, reflecting the impact of dilution from recent financings and upcoming capital needs, though the company maintains a buy rating due to the promising HLHS opportunity.